Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Equity Ratio (2016 - 2025)

UroGen Pharma's Equity Ratio history spans 10 years, with the latest figure at 0.53 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 1607.75% year-over-year to 0.53; the TTM value through Dec 2025 reached 0.53, down 1607.75%, while the annual FY2025 figure was 0.53, 1607.75% down from the prior year.
  • Equity Ratio reached 0.53 in Q4 2025 per URGN's latest filing, up from 0.62 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.79 in Q1 2021 to a low of 1.45 in Q2 2023.
  • Average Equity Ratio over 5 years is 0.25, with a median of 0.21 recorded in 2023.
  • Peak YoY movement for Equity Ratio: soared 138.96% in 2024, then tumbled 1607.75% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.07 in 2021, then plummeted by 1037.86% to 0.66 in 2022, then skyrocketed by 44.5% to 0.37 in 2023, then skyrocketed by 91.58% to 0.03 in 2024, then crashed by 1607.75% to 0.53 in 2025.
  • Per Business Quant, the three most recent readings for URGN's Equity Ratio are 0.53 (Q4 2025), 0.62 (Q3 2025), and 0.45 (Q2 2025).